Preclinical toxicologic evaluation of nadolol, a new β-adrenergic antagonist

Sibley, Peter L.; Keim, G. R.; Kulesza, J.S.; Murphy, Bernard F.; Myhre, J.; Parish, H. M.; Yoon, Yong‐Ho; Zaidi, Intestar H.

doi:10.1016/0041-008x(78)90198-9

Cited by 20 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ishibashi et al reported that 46 out of 136 pregnant women were successfully given beta-blocker without any major complications [7]. Safety of nadolol during pregnancy has also been proven [8]. Mazzanti et al demonstrated the superiority of nadolol in reducing the risk of lifethreating arrhythmic events compared to propranolol and metoprolol, and that only nadolol reduced the arrhythmic risk in all genotypes [4].…”

Section: Discussionmentioning

confidence: 99%

Successful trans-maternal nadolol pharmacotherapy in a fetus presenting with long QT syndrome type 2 complicated by torsade de pointes

Shima

Horigome

Nozaki

et al. 2020

Journal of Cardiology Cases

View full text Add to dashboard Cite

Fetuses with congenital long QT syndrome (LQTS) may experience life-threatening arrhythmias, such as torsade de pointes (TdP), and/or functional atrioventricular block. However, trans-maternal pharmacotherapy for these cases is rarely reported and management practices have yet to be established. The fetus of a mother with genetically-confirmed LQTS type 2 (LQT2) presented with complex arrhythmias, diagnosed via magnetocardiography as ventricular arrhythmias (including TdP), at 28 weeks of gestation. After initiation of trans-maternal nadolol administration at 15 mg/d initial dosage and 30 mg/d subsequent dosage, the frequency of fetal ventricular arrhythmias decreased and almost disappeared within several days. The mother gave birth to the baby at full term without significant complications in either the mother or fetus. This is the first report that demonstrates the efficacy and safety of transmaternal administration of nadolol for treatment of symptomatic LQT2 fetuses with TdP.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful trans-maternal nadolol pharmacotherapy in a fetus presenting with long QT syndrome type 2 complicated by torsade de pointes

Shima

Horigome

Nozaki

et al. 2020

Journal of Cardiology Cases

View full text Add to dashboard Cite

show abstract

“…1 Although animal studies suggest the lack of a teratogenie effect secondary to nadolol administration, no data concerning the use of the drug in pregnant women have been reported. 31 The drug does, however, cross the placental barrier in animal models. 2 As a consequence, the use of the drug during pregnancy must outweigh the potential risk to the fetus.…”

Section: Side Effects and Adverse Effectsmentioning

confidence: 99%